Email this Page
Print this Page 
CALGB 100801 - PHASE II STUDY OF THE ADDITION OF AZACITIDINE (IND #87574, NSC #102816) TO
CALGB 10801 - Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib with Myeloid Leukemia (AML)
CALGB 11001 - A Phase II Study Incorporating Sorafenib (IND 69896, NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
CALGB 50303 - Phase III Randomized Study of R-Chop V. Dose-Adjusted Epoch-R (DA-EPOCH-R) with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
CALGB 50604 - Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma
CALGB 50801 - Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
CALGB 50904 - Phase II Trial Ofatumumab & Bendamustine with & without Bortezomib in Untreated Foll. Lymphoma
ECOG 2905 - Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
GCC 0851 - Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response. BMT/CTN 0701
GCC 0922 - Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-cell Lymphomas. NCI Protocol 8064
GCC 0942 - A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually-Optimized Conditioning Using Pharmacokinetics [PK]-directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non- Hodgkins Lymphoma and Hodgkins Lymphoma
GCC 0952 - Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI-505, a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
GCC 0955 - Phase II Combination Immunotherapy after ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations with Hiltonol® (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T cells Followed by Lenalidomide Maintenance
GCC 0960 - A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib
GCC 1001 - Pharmacologic and Microbial Assessment of Saliva in Multiple Myeloma Patients at Risk for Bisphosphonate-Related Osteonecrosis of the Jaw
GCC 1027 - Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
GCC 1034 - A Phase 1b Study of GDC-0449 following autologous transplantation in patients with high risk first remission or relapsed multiple myeloma
GCC 1038 - A Phase III, Double-Blind, Randomized, Placebo-Controlled,Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy,Hematopoietic Cell Transplants (HCTs)
GCC 1056 - Phase I/IIa dual-cohort, two-site, clinical trial evaluating the safety and activity of redirected autologous T cells expressing a high-affinity TCR specific for MAGE-A3/6 or NY-ESO-1 administered post-ASCT in patients with advanced myeloma
GCC 1080 - A single-arm, open-label, multi-center study of complete molecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
GCC 1082 - A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine
GCC 1135 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
GCC 1146 - A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
GCC 1149 - Carfilzomib Multiple Myeloma Expanded Access Protocol (C-MAP) for Patients with Relapsed and Refractory Disease
GCC 1150 - A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications.
GCC 1158 - A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients with Previously Treated Multiple Myeloma
GCC 1164 - Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma
GCC 1168 - A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL
GCC 1169 - A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL
GCC 1179 - Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients with Hematological Malignancies. Protocol 2011-001
GCC 1180 - A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
GCC 1226 - A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy
GCC0940 - A Phase 1 Study of the PARP inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias
GCC0954 - Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in adult Acute Myeloid Leukemia patients
GCC1022 - A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995, IND#61198) plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults with Relapsed and Refractory Disease
GCC1062 - A Phase 1/2 Study of SNDX-275 in Combination with Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
GCC-1068 - A PILOT STUDY TO EVALUATE THE EFFICACY AND EXPLORE THE MECHANISM OF ACUPUNCTURE IN TREATING BIPN IN MM PATIENTS
GCC1078 - A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
GCC1105 - Randomized Phase II Trial of timed Sequential Therapy (TST) with Alvocidib (Flavopiridol), ara-C and mitoxantrone (FLAM) vs. "7+3" for Adults age 70 and Under with Newly Diagnosed Acute Myelogenous Leukemia (AML)
GCC1106 - A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Azacitidine in Patients with the Myelodysplastic Syndrome (MDS)
GCC1138 - Phase 2 Trial of R115777 in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
GCC1160 - AN OPEN LABEL ASSESSMENT OF AN ALTERNATIVE DOSING STRATEGY OF RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA-MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA-MYELOFIBROSIS
GCC1182 - A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension)
SWOG 0535 - A Phase II Study of Atra, Arsenic Trioxide And Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
SWOG 0805/HP-00047377 - S0805, "Phase II Study of Combination of Hyper-CVAD and Dasatinib with or
|
Email this Page
Print this Page
|
